CL
APLS

CSS LLC’s Apellis Pharmaceuticals APLS Stock Holding History

CSS LLC’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Buy
+45,000
New +$970K 0.09% 177
2022
Q4 		– Sell
-21,000
Closed -$1.43M – 949
2022
Q3 		$1.43M Buy
+21,000
New +$1.24M 0.07% 277
2022
Q2 		– Sell
-5,100
Closed -$259K – 1099
2022
Q1 		$259K Buy
+5,100
New +$225K 0.01% 785
2020
Q2 		– Sell
-4,500
Closed -$121K – 661
2020
Q1 		$121K Sell
4,500
-32,600
-88% -$1.16M 0.01% 478
2019
Q4 		$1.14M Buy
+37,100
New +$1.03M 0.06% 231

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CSS LLC's APLS Position: Q1 2026 in Review

CSS LLC opened a new position in Apellis Pharmaceuticals (APLS) in Q1 2026: 42,818 shares worth $1.72M. The stake represents 0.08% of the portfolio and ranks #185 among its holdings. This is a return to the name: CSS LLC previously reported a position in APLS as recently as Q1 2022.

CSS LLC first reported a position in APLS in Q1 2022 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • CSS LLC held 42,818 shares of Apellis Pharmaceuticals worth $1.72M as of Q1 2026.
  • Apellis Pharmaceuticals was a new CSS LLC position in Q1 2026.
  • Apellis Pharmaceuticals made up 0.08% of CSS LLC's portfolio in Q1 2026, its #185 holding.
  • CSS LLC first reported a position in Apellis Pharmaceuticals in Q1 2022 and has held it in 2 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on CSS LLC's 13F filing for Q1 2026, filed 15 May 2026.